anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The long non-coding RNA (lncRNA), NEAT1, has emerged as a central figure in the intricate network of molecular regulators in inflammatory infectious diseases (IIDs). The review initiates a comprehensive exploration of NEAT1's multifaceted roles and molecular interactions in the context of these complex diseases. The study begins by acknowledging the global health burden of IIDs, underscoring the urgency for innovative insights into their pathogenesis and therapeutic avenues. NEAT1 is introduced as a pivotal lncRNA with growing relevance in immune responses and inflammatory processes. The core of this review unravels the NEAT1 landscape, elucidating its involvement in the modulation of immune signalling pathways, regulation of inflammatory cytokines, and interactions with various immune cells during infection. It explores NEAT1's role in orchestrating immune responses and balancing host defence mechanisms with the risk of immunopathology. Furthermore, the review underscores the clinical significance of NEAT1 in infectious diseases, discussing its associations with disease severity, prognosis, and potential as a diagnostic and therapeutic target. It provides insights into ongoing research endeavours aimed at harnessing NEAT1 for innovative disease management strategies, including developing RNA-based therapeutics. Concluding on a forward-looking note, the review highlights the broader implications of NEAT1 in the context of emerging infectious diseases and the possibility for precision medicine approaches that leverage NEAT1's regulatory capacities. In summary, this review illuminates the pivotal role of NEAT1 in IIDs by navigating its complex landscape, offering profound insights into its implications for disease pathogenesis and the development of targeted therapies.
Wearable devices that predict the context in which they are used based on previously tracked context data, and methods associated with the same, are provided. A wearable device may include a processor, a sensor that records data associated with a user of the wearable device, and memory storing executable instructions. By way of executing the instructions, the wearable device may receive context data representing a first context from the user. The wearable device may correlate the received context data with a first set of recorded sensor data. A second set of recorded sensor data may be recorded subsequent to recording the first set of recorded sensor data. The wearable device may then predict a second context associated with the second set of recorded sensor data based on the correlation between the context data received from the user and the first set of recorded sensor data.
Short sleep duration (\<6.5 hours per night) is a risk factor for poorer health outcomes,1 including overweight and obesity,2 likely due, in part, to its impact on energy intake and eating behaviors. Previous research with experimental sleep restriction and observational studies of short sleepers has shown that short sleep duration is associated with higher calorie intake (including greater calories from fat), increased hunger ratings, a greater number of daily eating occasions, and consumption of larger food portion sizes.3 Short sleep duration is also related to cardiovascular risk factors, including hypertension.4 Sleep extension studies provide some evidence that increasing time spent asleep at night may improve weight, eating behaviors (e.g., net reduction of 270 kcal/d and 0.87 kg over 4 weeks5), and cardiovascular outcomes (e.g., blood pressure6); however, the current literature is limited by short-term intervention and study periods (e.g., 2 to 9 weeks). Therefore, it is unclear if the effects of sleep extension can be sustained over time and if a longer intervention can produce clinically meaningful weight reduction and associated health improvements in adults with obesity. This pilot study will determine the feasibility of a longer, 16-week sleep extension intervention to increase nighttime sleep duration among 10 adults, aged 18-50 years old, with obesity (BMI \> 30 kg/m2). Additional secondary outcomes of changes in weight, eating behaviors, wellbeing, and blood pressure will also be assessed. If results are positive, the protocol will be used to secure external funding for a larger randomized clinical trial.
INTRODUCTION: Adolescents presenting with medically unexplained symptoms (MUS) in non-mental healthcare settings, particularly Emergency Departments (EDs), pose diagnostic challenges necessitating a comprehensive bio-psycho-social approach. Amid the youth mental health crisis, recognising psychological distress is imperative. This study delved into physicians' perceptions and diagnostic tendencies regarding such cases, exploring the potential overshadowing of psychosomatic presentations by medicalized diagnoses in EDs.
METHODS: Our study involved 74 physicians, representing 82% of eligible respondents in the Paediatric Emergency Medicine Department, and was conducted using an online questionnaire examining perceptions of case scenarios with psychosomatic presentations.
RESULTS: Results disclosed a prevalent inclination toward medical diagnoses, with less than 10% of physicians considering psychosomatic conditions in specific scenarios. Interestingly, psychosomatic diagnoses were more probable for symptoms like headaches, shortness of breath, and chest pain. The study uncovered a possible bias among physicians towards medical diagnoses in EDs for adolescents with MUS, possibly stemming from physicians' focus on physical care, diagnostic uncertainties, cognitive biases, and concerns about stigmatisation.
CONCLUSION: Adolescents with MUS seeking assistance in non-mental health settings may encounter delayed mental health diagnoses and interventions. Psychosomatic symptoms could signify stressors or underlying mental health disorders. Recognising psychosocial distress early on is crucial for optimal mental health outcomes. Consequently, the study advocates for a paradigm shift towards a holistic bio-psychosocial approach in both medical education and practice.
Previous studies have suggested that levels of sodium and chloride in the blood may be indicative of the prognosis of different medical conditions. Nevertheless, the assessment of the prognostic significance of the sodium-to-chloride (Na/Cl) ratio in relation to in-hospital mortality among individuals suffering from acute heart failure (AHF) remains unexplored. In this study, the participants were selected from the Medical Information Mart for Intensive Care IV database and divided into three groups based on the Na/Cl ratio level upon admission. The primary results were the mortality rate within the hospital. Cox regression, Kaplan-Meier curves, receiver operator characteristic (ROC) curve analysis and subgroup analyses were utilized to investigate the correlation between the admission Na/Cl ratio and outcomes in critically ill patients with AHF. A total of 7844 patients who met the selection criteria were included in this study. After adjusting for confounders, the multivariable Cox regression analysis revealed that the baseline Na/Cl ratio significantly elevated the risk of in-hospital mortality among critically ill patients with AHF (HR = 1.34, 95% CI 1.21-1.49). Furthermore, when the Na/Cl ratio was converted into a categorical factor and the initial tertile was taken as a point of comparison, the hazard ratios (HRs) and 95% confidence intervals (CIs) for the second and third tertiles were 1.27 (1.05-1.54) and 1.53 (1.27-1.84), respectively. Additionally, a P value indicating a significant trend of < 0.001 was observed. ROC curve analysis showed that Na/Cl ratio had a more sensitive prognostic value in predicting in-hospital mortality of AHF than the sodium or chloride level alone (0.564 vs. 0.505, 0.544). Subgroup examinations indicated that the association between the Na/Cl ratio upon admission and the mortality rate of critically ill patients with AHF remained consistent in the subgroups of hyponatremia and hypochlorhydria (P for interaction > 0.05). The linear relationship between the Na/Cl ratio and in-hospital mortality in AHF patients indicates a positive association.
Tricuspid annular enlargement in patients with atrial fibrillation (AF) can induce tricuspid regurgitation (TR). However, risk factors associated with TR progression in patients with AF have not been defined. This study aimed to clarify an association between tricuspid annular diameter (TAD) and TR progression in patients with longstanding persistent AF. We retrospectively analyzed data from 228 patients who had longstanding persistent AF for > 1 year and mild or less TR on baseline echocardiograms. We defined significant TR as moderate or greater TR, graded according to the jet area and vena contracta. The optimal cut-off value of the TAD index (TADI), based on body surface area for predicting progression to significant TR, was estimated using receiver operating characteristic (ROC) curves. The independence and incremental value of the TADI were evaluated using multivariate Cox proportional hazard regression analysis and likelihood ratio tests. Over a median follow-up of 3.7 years, 55 (24.1%) patients developed significant TR. The optimal cut-off value of 21.1 mm/m2 for the TADI at baseline and ROC curves predicted TR progression with 70.4% sensitivity and 86% specificity. Furthermore, TADI was an independent predictor of TR progression (hazard ratio, 1.32; 95% confidence interval, 1.17-1.49, P < 0.001) and had a significant incremental value that exceeded that of models constructed using clinical parameters. In conclusion, TADI was significantly associated with TR progression and was an independent predictor of TR progression in longstanding persistent AF.
The active ingredients of Edarbyclor target two separate mechanisms involved in blood pressure regulation.

Azilsartan medoxomil

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principle pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis. 

An AT 2receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT 1receptor than for the AT 2receptor. 

Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation.

Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure.

Chlorthalidone

Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the distal renal tubule (early convoluted part), inhibiting NaCl reabsorption (by antagonizing the Na+-Cl-cotransporter) and promoting Ca++ reabsorption (by an unknown mechanism). The enhanced delivery of Na+ and water to the cortical collecting tubule and/or the increased flow rate leads to increased secretion and elimination of K+ and H+. The diuretic effects of chlorthalildone lead to decreased extracellular fluid volume, plasma volume, cardiac output, total exchangeable sodium, glomerular filtration rate, and renal plasma flow. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.
The invention provides a systematic separation and purification method of corydalis alkaloid. The preparation liquid chromatogram is adopted to efficiently separate and purify alkaloid monomers from alkaloid components, and the separation modes are reversed phase chromatogram and ion exchange chromatogram. The mobile phase consists of acetonitrile, methanol or ethanol with water (with the addition of a certain amount of acid or buffer salt). Linear gradient, step gradient or isocratic elution mode is adopted. Preparing the rhizoma corydalis micro-alkaloid component, the constant tertiary amine alkali component and the quaternary ammonium alkali component by two-dimensional reversed phase/reversed phase, reversed phase and ion exchange chromatography modes respectively. The method can realize the target preparation of alkaloid, can obtain batch of known active alkaloid, and simultaneously enrich and separate trace alkaloid, thereby continuously enriching alkaloid library and providing material basis for the activity research of alkaloid compounds and the development of new drugs with single component.
Apparatus for monitoring an infant comprises infant unit 2, arranged to be located near an infant, which includes a plurality of sensors 4 and a processing unit 20. The processing unit analyses sensory data from at least one of the sensors, algorithmically interprets the data, and autonomously responds directly at the infant unit and/or triggers a remote alarm at a wirelessly coupled parent unit 8. The processing unit may use a pre-trained machine learning algorithm such as a neural network to categorise different kinds of event from the sensor data. The accuracy of the machine learning algorithm may be reinforced by sensor data. The processing unit may analyse the frequency and amplitude characteristics of sound data received in the sensory data. The parent unit may include a user interface through which alarm thresholds can be adjusted. In a second aspect, apparatus for monitoring an infant includes an integrated projector capable of projecting video and images onto a surface.
The gut microbiome plays a significant role in developing colorectal cancer (CRC). The gut microbiome usually acts as a protective barrier against harmful pathogens and infections in the intestine, while also regulating inflammation by affecting the human immune system. The gut microbiota and probiotics play a role not only in intestinal inflammation associated with tumor formation but also in regulating anti-cancer immune response. As a result, they associated with tumor progression and the effectiveness of anti-cancer therapies. Research indicates that gut microbiota and probiotics can be used as biomarkers to predict the impact of immunotherapy and enhance its efficacy in treating CRC by regulating it. This review examines the importance of gut microbiota and probiotics in the development and progression of CRC, as well as their synergistic impact on anti-cancer treatments.
Twenty marital dyads from the site randomly assigned as the intervention site(s) will receive the 12- week peer leader-facilitated dyadic intervention. Topics over the 12 week intervention will address stress management, family history and genetic risk, dietary habits, physical activity and social support/community engagement.
Each Orphenadrine Citrate, Aspirin and Caffeine Tablet, for oral administration contains Orphenadrine Citrate 50 mg, Aspirin 770 mg and Caffeine 60 mg.

In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, D&C yellow #10, FD&C blue #1, zinc stearate, povidone, pregelatinized starch, and stearic acid.

Orphenadrine citrate is (2-dimethylaminoethyl 2-methylbenzhydryl ether citrate). It is a white, practically odorless, crystalline powder, having a bitter taste. It is sparingly soluble in water; slightly soluble in alcohol. It has the following structural formula:

Aspirin, salicylic acid acetate, is a non-opiate analgesic, anti-inflammatory and antipyretic agent It occurs as a white, crystalline tabular or needle-like powder and is odorless or has a faint odor. It is sparingly soluble in water, freely soluble in alcohol and chloroform. It has the following structural formula:

Caffeine is a central nervous system stimulant which occurs as a white powder or white glistening needles, usually matted together. It is sparingly soluble in alcohol, and freely soluble in chloroform. The chemical name for caffeine is, 1,3,7-Trimethylxanthine. It has the following structural formula:
FIELD: cellular biology, biophysics. SUBSTANCE: invention proposes cytotoxic composition for damage of target- cells consisting of component for recognition of target-cells and realization by them receptor-mediated endocytosis, component for directed intracellular transport into nucleus, component-carrier for assembling and stabilization of composition and properly damaging agent astatine-211 bound with protein moiety of composition in the ratio providing the cytotoxic effect. Prepared specific species of the composition characterizing by structure (modified sequence of signal of nucleus localization of T-antigen SV-40 component for intracellular transport) - (β--galactosidase-carrier) (insulin component for recognition and endocytosis) (astatine-211) and by ratio astatine-211/protein that is sufficient for preparing the composition with specific radioactivity 5 MBq/mg, not less, allows owing to the directed effect to obtain the expressed cytotoxic effect (in part, in cells of liver hepatoma) in using the preparation with specific activity by about 10 times lesser as in the case of free radionuclide. Invention provides possibility for damage of cells of definite type, for example, tumor cells in relatively low concentrations of radionuclide and minimal effect on surrounding tissues. Invention can be used in medicinal practice and pharmacology. EFFECT: enhanced effectiveness, valuable properties of composition. 6 cl, 3 dwg
The invention discloses a preparation of Chinese medicine for venous thrombosis after joint replacement. The preparation comprises the raw materials of Radix Astragali, Ligusticum wallichii, red sage root, Aconitum carmichaelii, Cyperus Rotundus L, corydalis tuber, cyathula root, white peony root, cassia twig, clematis root, safflower, spatholobus stem, notopterygium root, levisticum, leech, ground beetle, Artemisia anomala, frankincense, myrrh, gadfly, sparganium and curcuma rhizome and belongs to the invention field of traditional Chinese medicine. According to different characteristics of each Chinese medicament in the above preparation, after the raw materials are washed, cut into blocks and pre-treated, the raw materials are compounded in proportion and prepared through a special means to prepare the above preparation. The obtained preparation has the advantages of promoting circulation, removing stasis, extinguishing embolism and relaxing veins. The composition of the preparation and the method for preparing the preparation are unique. It has been verified by clinical experiments that, the preparation is obvious in treatment effect, short in treatment period, low in price, free of any adverse reaction or toxic/side effect, and broad in market application prospect.
The invention provides adenoviral coat proteins comprising various non-native ligands. Further, the present invention provides an adenoviral vector that elicits less reticulo-endothelial system (RES) clearance in a host animal than a corresponding wild-type adenovirus. Also provided by the invention is a system comprising a cell having a non-native cell-surface receptor and a virus having a non-native ligand, wherein the non-native ligand of the virus binds the non-native cell-surface receptor of the cell. Using this system, a virus can be propagated. Further provided by the invention is a method of controlled gene expression utilizing selectively replication competence, a method of assaying for gene function, a method of isolating a nucleic acid, and a method of identifying functionally related coding sequences. Additionally, the invention provides a cell-surface receptor, which facilitates internalization.
Bortezomib is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied.

Monitor complete blood counts (CBC) frequently during treatment with bortezomib. Measure platelet counts prior to each dose of bortezomib. Adjust dose/schedule for thrombocytopenia [see Dosage and Administration (2.6)] . Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with bortezomib. Support with transfusions and supportive care, according to published guidelines. 

In the single-agent, relapsed multiple myeloma study of bortezomib vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 8. The incidence of bleeding (≥Grade 3) was 2% on the bortezomib arm and was <1% in the dexamethasone arm. 

* A baseline platelet count of 50,000/μL was required for study eligibility   
‡Data were missing at baseline for one patient 

In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12. The incidence of bleeding events (≥Grade 3) was 1.7% in the BR-CAP arm (four patients) and was 1.2% in the R-CHOP arm (three patients). 

Platelet transfusions were given to 23% of the patients in the BR-CAP arm and 3% of the patients in the R-CHOP arm.

The incidence of neutropenia (≥Grade 4) was 70% in the BR-CAP arm and was 52% in the R‑CHOP arm. The incidence of febrile neutropenia (≥Grade 4) was 5% in the BR-CAP arm and was 6% in the R-CHOP arm. Myeloid growth factor support was provided at a rate of 78% in the BR-CAP arm and 61% in the R-CHOP arm.
A medication guidance system that securely stored blister packs as well as keep accurate inventory of specific medication within the blister packs. The medication guidance system includes a drawer housing, a blister pack drawer, a latch mechanism, a plurality of light sources, a plurality of cameras, and a microcomputer. The drawer housing is the structural body and holds the blister pack drawer through a drawer hole. The blister pack drawer is slidably positioned within the drawer hole. The light sources and the cameras are positioned within the drawer housing and oriented towards the blister pack drawer to visually identify the contents placed within the blister pack drawer. The data taken by the cameras is graphically analyzed by the microcomputer for inventory and identification purposes. The latch mechanism is mechanically integrated in between the drawer housing and the blister pack drawer to manage access to the blister pack drawer.